Alphabet's AI Drug Discovery Startup Isomorphic Labs Secures $600M in Landmark Funding Round

Curated by THEOUTPOST

On Mon, 31 Mar, 4:05 PM UTC

10 Sources

Share

Isomorphic Labs, an AI-driven drug discovery platform spun out from Google's DeepMind, has raised $600 million in its first external funding round. The investment, led by Thrive Capital, aims to accelerate AI-powered drug development and bring AI-designed drugs to clinical trials.

Isomorphic Labs Secures $600M in Landmark Funding Round

Isomorphic Labs, the AI-driven drug discovery platform spun out of Google's DeepMind in 2021, has successfully raised $600 million in its first external funding round. The investment was led by Thrive Capital, with participation from GV and existing investor Alphabet, Google's parent company 123.

Strategic Partnerships and Nobel Recognition

Prior to this funding round, Isomorphic Labs had already made significant strides in the pharmaceutical industry. In 2024, the company secured strategic partnerships with pharmaceutical giants Eli Lilly and Novartis, potentially generating up to $3 billion in milestone payments for access to its AI model 1. The company's founder, Demis Hassabis, along with DeepMind researcher John Jumper, received a Nobel Prize in chemistry in 2024 for their work on AlphaFold, an AI model that predicts the three-dimensional structures of proteins 13.

Accelerating AI-Powered Drug Discovery

The substantial funding will be utilized to accelerate the development of Isomorphic's AI drug design engine and support the company's ambitious goal of bringing AI-discovered drugs to clinical trials 14. Demis Hassabis, CEO of Isomorphic Labs, stated that the investment will "turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI" 35.

Expanding Research and Development

Isomorphic Labs plans to use the funds to expand its research and development efforts, as well as to acquire top talent in the field 13. The company leverages advanced AI technologies, including AlphaFold and proprietary AI models, to run predictions and simulate drug development 3. In May 2024, DeepMind unveiled AlphaFold 3, an AI model capable of predicting the structures of genetic code DNA and RNA, as well as ligands, which are crucial molecules in disease markers 3.

Financial Performance and Growth

While specific financial details such as valuation were not disclosed, Isomorphic Labs reported losses of £60 million in 2023, up from £17 million the previous year. However, the company has significantly increased its R&D costs to £49 million and tripled its staff costs to £20 million, with a headcount of 71 3. This substantial investment and growth in operations underscore the company's commitment to advancing AI-driven drug discovery.

Industry Impact and Future Prospects

The funding round for Isomorphic Labs is among the largest for a UK AI company and reflects the growing interest in AI-powered drug discovery 3. Josh Kushner, founder and CEO of Thrive Capital, expressed confidence in Isomorphic's potential, stating, "We believe Isomorphic has earned a rare position to define a new age of drug discovery and design" 3. With this significant financial boost, Isomorphic Labs aims to have AI-designed drugs in clinical trials by the end of 2025, potentially revolutionizing the pharmaceutical industry 4.

Continue Reading
Google DeepMind CEO Predicts AI-Designed Drugs in Clinical

Google DeepMind CEO Predicts AI-Designed Drugs in Clinical Trials by 2025

Demis Hassabis, CEO of Google DeepMind and founder of Isomorphic Labs, announces that AI-designed drugs are expected to enter clinical trials by the end of 2025, potentially revolutionizing drug discovery and development.

TelecomTalk logoQuartz logoFinancial Times News logotheregister.com logo

7 Sources

TelecomTalk logoQuartz logoFinancial Times News logotheregister.com logo

7 Sources

Latent Labs Emerges with $50M to Revolutionize Drug

Latent Labs Emerges with $50M to Revolutionize Drug Discovery Using AI

Latent Labs, founded by former DeepMind scientist Simon Kohl, launches with $50 million in funding to develop AI models for protein design and accelerate drug discovery.

SiliconANGLE logoSilicon Republic logoTechCrunch logoFinancial Times News logo

4 Sources

SiliconANGLE logoSilicon Republic logoTechCrunch logoFinancial Times News logo

4 Sources

Basecamp Research Raises $60M to Build 'ChatGPT for Nature'

Basecamp Research Raises $60M to Build 'ChatGPT for Nature' and Advance AI in Biology

Basecamp Research, a London-based startup, has secured $60 million in Series B funding to develop AI models for life sciences, aiming to create a 'ChatGPT for nature' by collecting and analyzing vast amounts of biological data.

Silicon Republic logoSiliconANGLE logoTechCrunch logoBenzinga logo

4 Sources

Silicon Republic logoSiliconANGLE logoTechCrunch logoBenzinga logo

4 Sources

OpenAI and Thrive Capital Invest in AI Drug Discovery

OpenAI and Thrive Capital Invest in AI Drug Discovery Startup Profluent

OpenAI and Thrive Capital have backed Profluent, a six-month-old AI drug discovery startup, in a significant funding round. The investment highlights the growing interest in AI applications for pharmaceutical research.

Bloomberg Business logo

2 Sources

Bloomberg Business logo

2 Sources

Google DeepMind and BioNTech Join Forces to Revolutionize

Google DeepMind and BioNTech Join Forces to Revolutionize Scientific Research with AI Lab Assistants

Google DeepMind and BioNTech have announced a collaboration to develop AI-powered lab assistants, aiming to accelerate scientific research and drug discovery. This partnership combines DeepMind's AI expertise with BioNTech's biotech prowess to create more efficient and innovative research processes.

Benzinga logoFinancial Times News logo

2 Sources

Benzinga logoFinancial Times News logo

2 Sources

TheOutpost.ai

Your one-stop AI hub

The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.

© 2025 TheOutpost.AI All rights reserved